Strategic Partners
GreenLine collaborates with globally recognized biotechnology manufacturers to provide laboratories with validated diagnostic technologies, supported locally through scientific expertise and responsive technical service.
Our partnerships are built on shared commitment to quality, scientific rigor and long-term collaboration
PARTNERS PROFILES
a biomolecular diagnostic company breaking barriers to precision oncology, working as a companion diagnostic aiming to help patients benefit from targeted therapy, founded in Xiamen, China in 2008, AmoyDx provides >1000,000 clinical diagnostic oncology tests per year in more than 75 countries worldwide.
AmoyDx delivers a comprehensive portfolio of oncology molecular diagnostics designed to support accurate, timely, and clinically actionable decision-making. The company offers a wide range of PCR-based assays alongside advanced NGS panels, covering key solid tumor indications and critical therapeutic biomarkers. AmoyDx tests are recognized for their high analytical sensitivity, streamlined workflows, and strong clinical validation, enabling reliable mutation detection from challenging sample types, including FFPE and liquid biopsy. With a focus on practical implementation, AmoyDx solutions are supporting laboratories and clinicians with robust, scalable, and cost-effective precision oncology testing.
GeneMind Biosciences is a rapidly growing molecular diagnostics company focused on advancing precision medicine through accessible, high-performance next-generation sequencing (NGS) full solutions. The company offers a comprehensive portfolio of sequencing platforms ranging from low- to high-throughput systems together with a range of reagents, and optimized workflows from Shenzhen China to more than 55 countries around the world to enable laboratories to scale genomic testing according to clinical and operational needs.
GeneMind Biosciences delivers a comprehensive next-generation sequencing ecosystem supporting laboratories across the entire NGS workflow. Driven by strong internal research and development capabilities, GeneMind is a fast-growing organization continuously expanding its product portfolio of NGS sequencing platforms and applications, delivering the full NGS solutions to laboratories.
GeneMind solutions are designed with a strong focus on user-friendly operation and workflow efficiency, ensuring ease of use without compromising analytical performance. The company’s technologies are recognized for their high precision, specificity, and reproducibility, delivering reliable and clinically meaningful results, while maintaining cost-effective testing models. Most GeneMind instruments and assays are CE-IVD certified, reinforcing the company’s commitment to quality, regulatory compliance, and consistent performance in routine laboratory practice.
Founded in the United Kingdom in 1983, The Binding Site—part of Thermo Fisher Scientific—is a global leader in protein diagnostics, delivering high-impact solutions in hematology and immunology that directly influence patient management. Through proprietary assays and automated protein analysis on the Optilite® platform, the company enables laboratories worldwide to deliver reliable, guideline-aligned testing with operational efficiency and clinical confidence.
The Binding Site, part of Thermo Fisher Scientific, offers a specialized portfolio of protein analysis solutions with a strong focus on hematology and plasma cell disorders. Its Freelite® assays, widely referenced by their commercial name in international clinical guidelines and recommendations, play a critical role in the diagnosis, prognosis, and monitoring of multiple myeloma, monoclonal gammopathies and related disorders. Complementing this, the Hevylite® assay represents a patented and unique innovation, enabling precise measurement of intact immunoglobulin heavy/light chain pairs, providing clinically valuable insights not achievable with conventional testing.
In addition to hematology, Optilite® supports a comprehensive test menu including multiple sclerosis KFLC index and complement testing such as CH50, alongside a wide range of protein assays, making it a versatile solution for advanced immunology and protein analysis laboratories.
Founded in Amsterdam, MRC Holland is a biotechnology company internationally recognized for its SALSA® MLPA® technology, a widely adopted method for detecting gene copy number variations and methylation patterns associated with genetic diseases.
MLPA has become a global reference technique in clinical genetics laboratories for studying hereditary disorders, tumor genetics, and epigenetic alterations.
Through this partnership, GreenLine supports laboratories with reliable access to validated genetic testing solutions that enhance diagnostic accuracy and expand capabilities in molecular genetics.
LaCAR is a Belgian company established in 2013, dedicated to transforming global public health through cutting-edge diagnostic solutions.
LaCar MDx provides advanced diagnostic solutions for newborn screening (NBS), pharmacogenetics and genetic predispositions testing.
The innovative technologies enable laboratories to provide accurate and accessible care, contributing to a better quality of life for all.
LaCAR offers complete and integrated diagnostic solutions, including kits, software, and automated instruments, designed to meet the diverse needs of clinical laboratories.
For newborn screening (NBS), LaCAR provides comprehensive solutions for the early detection of rare congenital, genetic, and metabolic disorders in newborns, such as PKU, Total Galactose, Biotinidase, SMA, and SCID and more. These tests utilize technologies including immunoassay, mass spectrometry, and DNA analysis, enabling early detection from heel-prick dried blood spot samples. The assays can be performed using modular ELISA setups, as well as semi-automated or fully automated workflows, depending on laboratory requirements and throughput.
In pharmacogenetics, LaCAR offers no-DNA-extraction diagnostic kits to identify genetic predispositions affecting the metabolism of various drugs, such as immune-suppressants and NSAIDs. This portfolio also includes the DPD test for detection of the enzyme encoded by the DPYD gene, which is involved in the metabolism of fluorouracil and and capecitabine chemotherapy, enabling identification of patients at risk of life-threatening fluorouracil toxicity.
No-DNA-extraction diagnostic kits are also available for the identification of genetic predispositions related to food intolerances, genetic thrombosis, and other inherited conditions